Novel Treatment Options for AML and Overview of Related Trials - Moving from Standard 7+3 to Combinations and Targeting FLT3, CD33, BCL2 and IDH Inhibitors

374 views
July 19, 2019
0 Comments
Login to view comments. Click here to Login